Skip to main content
. 2019 Nov 26;10(63):6805–6815. doi: 10.18632/oncotarget.27308

Figure 3. Survival outcomes for patients classified by the number of overexpressing NKG2D ligands.

Figure 3

NKG2D-L 0-1: none or one NKG2D ligand expressing tumor, NKG2D-L 2-3: 2 or 3 NKG2D ligand expressing tumor, NKG2D-L 4-5: 4 or 5 NKG2D ligand expressing tumor.